These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 15598035)

  • 21. A long-lasting response to sorafenib treatment in an advanced hepatocellular carcinoma patient.
    Di Lorenzo G; Imbimbo M; Leopardo D; Marciano R; Federico P; Buonerba C; Salvatore B; Marinelli A; Palmieri G
    Int J Immunopathol Pharmacol; 2010; 23(3):951-4. PubMed ID: 20943068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Gastrointestinal hemorrhage associated with concurrent use of sorafenib and warfarin for hepatocellular carcinoma].
    Shiozawa K; Watanabe M; Hirano N; Wakui N; Kikuchi Y; Hara F; Ishii K; Iida K; Sumino Y
    Gan To Kagaku Ryoho; 2011 Oct; 38(10):1713-5. PubMed ID: 21996974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Sorafenib for the treatment of HCC--the beginning of a new era in the treatment of HCC].
    Greten TF; Manns MP; Malek N
    Z Gastroenterol; 2009 Jan; 47(1):55-60. PubMed ID: 19156592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sorafenib for HCC: a pragmatic perspective.
    Razumilava N; Gores GJ
    Oncology (Williston Park); 2011 Mar; 25(3):300, 302. PubMed ID: 21548475
    [No Abstract]   [Full Text] [Related]  

  • 25. Hepatocellular carcinoma: sorafenib before liver transplantation?
    Braillon A
    Hepatology; 2010 Jun; 51(6):2232-3. PubMed ID: 20041410
    [No Abstract]   [Full Text] [Related]  

  • 26. [Our experience of the treatment with sorafenib for unresectable hepatocellular carcinoma].
    Ishizaki M; Kaibori M; Matsui K; Nakatake R; Matsushima H; Sakaguchi T; Kwon AH
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2493-5. PubMed ID: 22202424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Candidacy for sorafenib in HCC patients: is there a slippery slope beyond a SHARP edge?
    Burak KW
    Oncology (Williston Park); 2011 Mar; 25(3):296, 298, 300. PubMed ID: 21548474
    [No Abstract]   [Full Text] [Related]  

  • 28. Health-related quality of life and sorafenib.
    Spinzi G; Terreni N
    Hepatology; 2010 Oct; 52(4):1523. PubMed ID: 20672386
    [No Abstract]   [Full Text] [Related]  

  • 29. [Use of sorafenib in patients with hepatocellular or renal carcinoma].
    Rosmorduc O; Chevreau C; Dielenseger P; Ederhy S; Goldwasser F; Grange JD; Mortier L; Neidhardt-Berard ME; Robert C; Scotté F; Seitz JF
    Gastroenterol Clin Biol; 2010 Mar; 34(3):161-7. PubMed ID: 20181452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sorafenib - a small molecule with big promise?
    Tadmor T; Tallman MS; Polliack A
    Leuk Lymphoma; 2010 Feb; 51(2):181-2. PubMed ID: 20001865
    [No Abstract]   [Full Text] [Related]  

  • 31. [Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].
    Reig M; Matilla A; Bustamante J; Castells L; de La Mata M; Delgado M; Moreno JM; Forner A; Varela M
    Gastroenterol Hepatol; 2010 Dec; 33(10):741-52. PubMed ID: 20851505
    [No Abstract]   [Full Text] [Related]  

  • 32. Sorafenib in advanced hepatocellular carcinoma.
    Palmer DH
    N Engl J Med; 2008 Dec; 359(23):2498; author reply 2498-9. PubMed ID: 19065750
    [No Abstract]   [Full Text] [Related]  

  • 33. Sorafenib and thyrotoxicosis.
    Barbaro D
    J Endocrinol Invest; 2010 Jun; 33(6):436. PubMed ID: 20631496
    [No Abstract]   [Full Text] [Related]  

  • 34. Sorafenib in unresectable intrahepatic cholangiocellular carcinoma: a case report.
    Pinter M; Sieghart W; Reisegger M; Wrba F; Peck-Radosavljevic M
    Wien Klin Wochenschr; 2011 Jan; 123(1-2):61-4. PubMed ID: 21240686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Commentary: Sorafenib -- the end of a long journey in search of systemic therapy for hepatocellular carcinoma, or the beginning?
    Abou-Alfa GK
    Oncologist; 2009 Jan; 14(1):92-4. PubMed ID: 19144679
    [No Abstract]   [Full Text] [Related]  

  • 36. Are there opportunities for chemotherapy in the treatment of hepatocellular cancer?
    Asghar U; Meyer T
    J Hepatol; 2012 Mar; 56(3):686-95. PubMed ID: 21971559
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sorafenib in liver cancer--just the beginning.
    Roberts LR
    N Engl J Med; 2008 Jul; 359(4):420-2. PubMed ID: 18650519
    [No Abstract]   [Full Text] [Related]  

  • 38. Sorafenib in hepatocellular carcinoma.
    Josephs DH; Ross PJ
    Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical observation of the treatment with combination of transcatheter arterial chemoembolization and sorafenib for hepatocellular carcinoma with lung metastasis].
    Duan F; Wang MQ; Liu FY; Wang ZJ; Song P
    Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):716-8. PubMed ID: 20021873
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New drugs: abatacept, sorafenib, and nelarabine.
    Hussar DA
    J Am Pharm Assoc (2003); 2006; 46(2):300-3. PubMed ID: 16602235
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.